文献速递淋巴瘤

相当比例经典霍奇金淋巴瘤复发实为克隆无关的第二原发淋巴瘤

A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

该研究对60例经典霍奇金淋巴瘤(cHL)患者的配对初诊与复发样本进行Ig/TCR重排克隆性检测及靶向突变分析,发现可确定克隆关系的34例中24例(71%)为克隆相关复发,10例(29%)为克隆无关复发;复发间隔>2年者可确定克隆关系者中约60%为第二原发cHL,5例>50岁患者病理复核结合分子结果符合潜在T细胞淋巴瘤。

要点

  • cHL复发中约29%为克隆无关的第二原发淋巴瘤,非原克隆复发。
  • 复发间隔>2年者中约60%可确定克隆关系者为第二原发cHL。
  • 5例>50岁患者经病理复核结合分子结果符合潜在T细胞淋巴瘤。

核心结论

  • cHL复发尤其是2年后复发,有时代表新的原发cHL或模拟cHL的T细胞淋巴瘤,需基于NGS的Ig/TCR克隆性检测和基因突变分析识别。
  • 鉴于显著的治疗后果,对疑似cHL复发进行分子检测对制定针对特定淋巴瘤表现的后续治疗策略至关重要。

研究设计与样本

  • 对60例cHL患者的配对初诊与复发样本进行Ig和TCR重排的深入克隆性检测,并辅以淋巴瘤相关基因的靶向突变分析。

主要发现

  • 120份初诊和复发样本中69份(58%)通过NGS检测到克隆性Ig重排。
  • 34例可确定克隆关系,其中24例(71%)为克隆相关复发cHL,10例(29%)为克隆无关cHL,后者经IG-NGS克隆性评估确定并经配对样本中主要互斥基因突变的识别所证实。
  • 复发间隔>2年的可确定克隆关系cHL患者中约60%表现为第二原发cHL。
  • 125份样本中14份(11%)检测到克隆性TCR基因重排,14份中7份检测到TCL相关基因突变。
  • 5例>50岁患者经回顾性病理复核结合分子结果符合潜在TCL。

临床怎么用

  • 作者认为,对cHL疑似复发进行分子检测对制定针对特定淋巴瘤表现的后续治疗策略至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite high cure rates in classic Hodgkin lymphoma (cHL), relapses are observed. Whether relapsed cHL represents second primary lymphoma or an underlying T-cell lymphoma (TCL) mimicking cHL is underinvestigated. To analyze the nature of cHL recurrences, in-depth clonality testing of immunoglobulin (Ig) and T-cell receptor (TCR) rearrangements was performed in paired cHL diagnoses and recurrences among 60 patients, supported by targeted mutation analysis of lymphoma-associated genes. Clonal Ig rearrangements were detected by next-generation sequencing (NGS) in 69 of 120 (58%) diagnoses and recurrence samples. The clonal relationship could be established in 34 cases, identifying clonally related relapsed cHL in 24 of 34 patients (71%). Clonally unrelated cHL was observed in 10 of 34 patients (29%) as determined by IG-NGS clonality assessment and confirmed by the identification of predominantly mutually exclusive gene mutations in the paired cHL samples. In recurrences of >2 years, ∼60% of patients with cHL for whom the clonal relationship could be established showed a second primary cHL. Clonal TCR gene rearrangements were identified in 14 of 125 samples (11%), and TCL-associated gene mutations were detected in 7 of 14 samples. Retrospective pathology review with integration of the molecular findings were consistent with an underlying TCL in 5 patients aged >50 years. This study shows that cHL recurrences, especially after 2 years, sometimes represent a new primary cHL or TCL mimicking cHL, as uncovered by NGS-based Ig/TCR clonality testing and gene mutation analysis. Given the significant therapeutic consequences, molecular testing of a presumed relapse in cHL is crucial for subsequent appropriate treatment strategies adapted to the specific lymphoma presentation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. van Bladel DAG, Stevens WBC, Kroeze LI, et al. A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma. Blood Adv. 2023. PMID: 37552109. doi:10.1182/bloodadvances.2023010412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。